Study of blinatumomab injection for a rare leukemia type
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new way to give blinatumomab (a drug that helps your immune system fight cancer) as a shot under the skin for a rare leukemia called MPAL. It includes three different groups of patients depending on their treatment history.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be diagnosed with a specific type of leukemia called MPAL that has a protein called CD19.
- You must be willing to come to the clinic for study visits and follow study rules.
- You must not have a serious, uncontrolled infection or be taking other cancer treatments (like chemotherapy or radiation) at the same time.
- Based on which group you fit into, you may need to be older or have health conditions that prevent strong chemo, have had at least one prior treatment, or have leukemia that returned after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways of giving blinatumomab (a drug that helps your immune system find and kill leukaemia cells): as a continuous intravenous (IV) infusion versus a simpler subcutaneous (under the skin) injection. It is for adults newly diagnosed with B-cell precursor ALL, and the goal is to see if the subcutaneous injection works just as well while being more convenient.
This trial tests a new combination of targeted immune therapy and chemotherapy for a rare type of acute leukemia. The goal is to see if this approach can help people whose leukemia does not fit into the usual categories, potentially improving their chances of remission.
This study tests a combination of two medicines, blinatumomab and revumenib, for people with a specific genetic form of leukemia (KMT2A). The goal is to see if adding revumenib helps the treatment work better and keeps the cancer in remission.
This study tests a new injectable drug called BLB101 compared to a standard treatment (Blincyto) for adults with a type of leukemia called B-ALL that has come back or not responded to treatment. It may help you if your leukemia has the CD19 protein and you have had 1 to 2 previous treatments.
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
This study tests a drug called blinatumomab for people whose leukemia returns in a very early, hidden way after a stem cell transplant. The goal is to see if this drug can clear those leftover leukemia cells and help keep the disease from coming back.
Hear when a new CD19 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.